Vol. 15 Issue 4 October - December / 2017
Published on website | Date : 2018-04-09 10:22:16
THE RELATION OF SERUM OMENTIN-1 LEVEL WITH INSULIN RESISTANCE IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME AND ITS RELATION WITH METFORMIN TREATMENT
Jumana M. Kareem, Zainab H. Hashim, Hala A. Almoayed
Background: Polycystic ovary syndrome (PCOS) is still a matter of research looking for the true pathogenesis of this enigmatic syndrome. Although the majority of cases are familial, genetic studies have failed so far to identify the specific genes involved. The presentations of PCOS are heterogeneous and may change throughout the lifespan, starting from adolescence to post-menopausal age, and may have health impaction later in life. Omentin-1 is a fat depot-specific secretory protein produced by visceral stromal vascular cells. Recent studies showed that omentin-1 is correlated inversely with obesity and insulin resistance.
Objective: To assess the serum omentin-1 concentration in PCOS women and the effect of metformin on omentin-1 level, to evaluate the role of omentin-1 on insulin resistance and hyperandrogenemia in PCOS women and to look for the correlation of omentin-1 with body mass index (BMI) in PCOS women.
Methods: Eighty women involved in this study; 40 women with PCOS diagnosed according to Rotterdam ESHRE/ASRMS 2003 criteria and 40 apparently healthy women considered as the control group. The participants were allocated into six groups: “10 obese women with PCOS (BMI ≥30 kg/m2, without metformin treatment)”. “10 obese women with PCOS (BMI ≥30 kg/m2, taking metformin)”. “10 non-obese women with PCOS (BMI <30 kg/m2, without metformin treatment)”. “10 non-obese women with PCOS (BMI <30 kg/m2, taking metformin)”. “20 obese controls and 20 non-obese controls. Blood samples were taken from them for estimation of fasting blood glucose, insulin and omentin-1 levels. Hirsutism score was also evaluated according to Ferriman–Gallwey score.
Results: There was a significant increase in omentin-1 in non-obese PCOS (taking metformin) (3.02±0.71) compared to obese PCOS (taking metformin) (1.59±1.48) (P value = 0.0132) and in PCO non-obese (taking metformin) (3.02±0.71) compared with control non-obese (1.96±1.65) (P value = 0.121). No significant correlation was found between serum omentin-1 level and insulin resistance as well as with hyperandrogenemia in any of the six study groups.
Conclusion: Omentin-1 is found to be inversely related to body weight in PCOS women. Serum omentin-1 level has no effect on insulin resistance and hyperandrogenism states.
Keywords: Polycystic ovaries PCOS, omentin, hyperandrogenemia, insulin resistance
Citation: Kareem JM, Hashim ZH, Almoayed HA. The relation of serum omentin-1 level with insulin resistance in patients with polycystic ovary syndrome and its relation with metformin treatment. Iraqi JMS. 2017; Vol. 15(4): 327-338. doi: 10.22578/IJMS.15.4.2
Some tools below are only available to our subscribers or users with an online account